Ewing’s Sarcoma of Kidney- a Rare Case

Bikash Bikram Thapa, Narayan Thapa, Bharat Bahadur Bhandari, Bhairab Kumar Hamal

Department of Surgery, Shree Birendra Hospital, Kathmandu, Nepal.

ABSTRACT

Ewing’s sarcoma of kidney is rare and aggressive tumor of young adult with diagnostic challenges. Clinical presentations and imaging are non specific. The diagnosis depends on histopathology and immunohistochemistry and treatment encompass multimodality approach. We present here a case of Ewing’s sarcoma kidney of a young adult managed in our institution.

Keywords: ewing’s sarcoma; nephrectomy; immunohistochemistry; CD99; therapy.

Introduction

Peripheral primitive neuroectodermal tumor/Ewing’s sarcoma (pPNET/EWS) is an aggressive type of sarcoma predominantly a malignant bone or soft tissue tumor of children and young adults. Primary Ewing’s sarcoma of the kidney is very rare tumor that was first described in 1975 by Seemayer and colleagues. The current study presents the first known case of renal pPNET in our institution. Renal ES usually affects at the age between 20 and 30 years. 25% – 50% present with metastatic disease commonly in the lung, liver, and bone. Tumor thrombi are reported frequently. Treatment strategies for renal ES include surgery, chemotherapy, and radiation. The main challenge of ES remains proper diagnosis and its confirmation facilitating a patient’s adequate treatment in duetime.

Case Report

A 23 year serviceman was evaluated for right flank pain and ultrasonography showed right renal mass. Urine routine examination, complete blood count, renal function, chest x-ray were within normal limits. Patient was subjected to contrast enhanced CT abdomen and pelvis (Figure 1) that revealed 8.4 x 7.4 x 7.5 cm sized heterogeneously enhancing soft tissue density mass in mid pole of right kidney abutting liver, IVC and duodenum with tumor thrombus in right renal vein with radiological diagnosis of right renal cell carcinoma.

Patient underwent right radical nephrectomy from right subcostal approach. Grossly the kidney measured 14 x 9 x 9 cm and on cut section the nodular solid tumor measures 6 x 5.4 x 3 cm with areas of haemorrhage and necrosis (Figure 2). The postoperative period was uneventful.

Histopathological report was diffusely infiltrated small blue round cell population in sheets of varying size. PAS stain shows glycogen in many of the cells. An immunohistochemical panel demonstrated strong expression of CD99. S-100, CD-45, CD56, TDT, WT1, ketatins and desmin are negative. The final report was renal mass consistent with Ewing’s Sarcoma (PNET).

Patient is currently under combination chemotherapy (EFT 2001 protocol)

Discussion

Stout described Ewing’s sarcoma in 1918 in ulnar nerve that contain small round blue cells arranging into rosettes. John Ewing further characterized these tumors describing them in the diaphysis of long bones. These tumors are neural crest cells in origin belonging to a family of tumors called primitive neuroectoderm tumors (PNETs). pPNETs are part of the EWS family of tumors with EWS differing on the fact that it lacks neuroectodermal features.

A peripheral primitive neuroectoderm tumor (pPNET) is a small round cell tumor that predominantly occurs in

Correspondence:
Bikash Bikram Thapa,
Department of Surgery, Shree Birendra Hospital, Chhauni.
E-mail: bbthapa@gmail.com.
bone and soft tissue; however, pPNET is occasionally reported in visceral organs, such as urogenital, intra abdominal and intra thoracic organs. pPNET of the kidney is an aggressive disease with a high metastatic potential7.

Clinical symptoms and signs are non specific, comprising a triad of flank or abdominal pain, palpable mass, and hematuria in decreasing order. Systemic symptoms such as weight loss (14.5 %) and fever (9.7 %) are indicative of the underlying malignant disease. Laboratory findings are mostly unremarkable, but elevated lactate dehydrogenase (LDH) and (neuron specific enolase (NSE) levels were reported8. Apart from a poorly defined, infiltrative large mass with necrotic and hemorrhagic areas, generally imaging studies do not reveal characteristic signs.

Diagnosis of pPNET is based on morphologic, immunohistochemical and genetic analyses. Small, round cells with hyperchromatic nuclei, scant to moderate cytoplasmics and occasional rosettelike structures are the hallmarks of pPNET of the kidney9. However, pPNET of the kidney must still be differentiated from other small round cell tumors, such as blastemal Wilms’ tumor, malignant lymphoma, small cell carcinoma, rhabdomyosarcoma, poorly differentiated synovial sarcoma and desmoplastic small roundcell tumors. Overexpression of surface membrane protein CD99 and nuclear staining of FLI1 (Friend Leukemia integration 1 transcription factor) are universal features of pPNET7,10.

Most cases of Ewing’s sarcoma of kidney were diagnosed following nephrectomy. The main challenge of ES remains proper diagnosis and its confirmation facilitating a patient’s adequate treatment in due time.11 ES benefits from a combined treatment.12 The EURO-E.W.I.N.G. 99 study recommends a multiagent chemotherapy delivered prior (VIDE induction therapy) and continued after local control (consolidation therapy consisting of VAI or VAC)12.

Surgery is superior for local control and is frequently carried out as the first line of treatment. In addition, surgical intervention may encompass cavotomy in cases of venous tumor thrombus and metastasectomy, e.g. of pulmonary nodules. Irradiation of the surgical site with 50–60 Gys, results in complete responses in terms of reducing residual local disease however general consensus is still lacking13. Presence of tumor thrombus in the inferior vena cava is associated with a higher rate of pulmonary metastatic embolism so more intense chemotherapy and/or extended fields of radiation is warranted14,14,15. The survival expectancy of patients for localized disease is 70 %, whereas the outcome of metastatic disease at initial diagnosis remains poor, with survival rates from 9 % to 41 %16. About 30 % – 40 % of patients with ES experience tumor recurrence11.

Conclusion

ES is a rare kidney tumor that affects young adults with rapid clinical progression and significant mortality owing to late diagnosis, early metastasis, and advanced stage at presentation. Therefore, patients benefit from a correct and early diagnostic approach, followed by combined modality therapy.

References


Fig.1

Figure 2